Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
Open Access
- 31 December 2010
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 46 (18), 3243-3250
- https://doi.org/10.1016/j.ejca.2010.08.001
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursAnnals of Oncology, 2010
- Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal CancerClinical Cancer Research, 2009
- A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumorsInvestigational New Drugs, 2007
- A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysBritish Journal of Cancer, 2006
- Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulamInvestigational New Drugs, 2005
- Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis CJournal of Viral Hepatitis, 2005
- The Cyclin-dependent Kinase Inhibitor CYC202 ( R -Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase PathwayCancer Research, 2004
- Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical TrialsAccounts of Chemical Research, 2003
- Release of cytokeratin‐18 and ‐19 fragments (TPS and CYFRA 21‐1) into the extracellular space during apoptosisJournal of Cellular Biochemistry, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000